$8.7 Million Flight Attendant Medical Research Institute (FAMRI) Grant to Fund Effort to Enhance Early Detection and Treatment
Flight Attendants, Food and Entertainment Industry Professionals, and Other Nonsmokers Exposed to Smoking Environments Recruited
For more information call (212) 241-2420 or e-mail us at email@example.com
Until bans on in-flight smoking took effect, beginning in 1988, flight attendants were regularly exposed to secondhand smoke. These men and women and other service industry professionals are now being recruited for a landmark series of clinical studies on the health effects of secondhand smoke on nonsmokers, taking place at the Mount Sinai Medical Center and other locations around the world.
Funded through a $8.7 million Flight Attendant Medical Research Institute (FAMRI) grant, the initiative will employ a multidisciplinary research and clinical program to enhance early detection and treatment of diseases related to secondhand smoke (SHS) exposure-including cancer, heart disease, emphysema, asthma, chronic bronchitis and osteoporosis.
The initiative, called the FAMRI-IELCAP Collaborative Network, is a joint effort between FAMRI and the International Early Lung Cancer Action Program (I-ELCAP), the largest collaborative CT screening effort in the world.
A total of 5,000 patients will be recruited, with an emphasis on workers in industries with a high degree of secondhand smoke exposure-including flight attendants, restaurant and entertainment professionals.
Stanley M. Rosenblatt, chairman of FAMRI, says, "My wife, Susan, and I established FAMRI in 1997 with $300 million from a court-approved partial settlement of a class-action lawsuit we had filed in 1991 in Miami-Dade County, Florida, on behalf of non-smoking flight attendants against the tobacco industry. Susan and I selected a majority of flight attendants to serve on the Board of Trustees. We know that early screening saves lives and we enthusiastically support the FAMRI-IELCAP Collaborative Network."
"Secondhand smoke is a vital issue for flight attendants and anyone who has been exposed, willingly or unwillingly, to secondhand smoke. The FAMRI-IELCAP Collaborative Network represents an important opportunity to help ensure that exposure to secondhand cigarette smoke doesn't equate to a death sentence for its accidental victims," says Elizabeth A. Kress, executive director of FAMRI.
"The good news is that we expect to show that it is possible to screen for disease caused by secondhand smoke early enough for effective treatment," says Dr. Claudia Henschke, Professor of Radiology at Mount Sinai School of Medicine. She is principal investigator of I-ELCAP and of the entire FAMRI-IELCAP Collaborative Network projects (see below).
The initiative will employ many disciplines, ranging from diagnostic imaging for early detection of disease combined with advanced image processing to laboratory development of key biomarkers.
The FAMRI-IELCAP Collaborative Network has planned three major projects, lasting five years, to:
- Determine the probability of specific respiratory diseases (emphysema, chronic bronchitis, bronchiectasis, focal pneumonia, lung and mediastinal cancer) among patients exposed to secondhand smoke, with the aim of developing appropriate screening programs. (The principal investigator is Dr. Claudia Henschke.)
- Assess the increased risk of cardiovascular disease from secondhand smoke, independent of other risk factors, and develop guidelines for a clinical screening program for cardiovascular diseases. (The principal investigator is Dr. David Yankelevitz at Mount Sinai School of Medicine.)
- Determine if increased levels of prostaglandins (PGE-M) in urine, a marker of inflammation, particularly of diseases of the lung, can be used as a biomarker of the effects of tobacco smoke. (The principal investigator Dr. Andrew Dannenberg, director of cancer prevention at NewYork-Presbyterian/Weill Cornell and the Henry R. Erle, M.D.- Roberts Family Professor of Medicine at Weill Cornell Medical College.)
Additionally, two pilot projects will be initiated each year. Interested participants must be 40 and over, and must have been exposed-either as a child or as an adult-to an environment where heavy smoking took place. All participants will receive a low-dose CT screening.
For more information, patients may call the Early Lung and Cardiac Action Program at Mount Sinai Medical Center at (212) 241-2937 or e-mail firstname.lastname@example.org.
According to a 2006 U.S. Surgeon General's report, secondhand smoke causes premature death and disease in children and in adults who do not smoke. Scientific evidence indicates that there is no risk-free level of exposure to secondhand smoke. Many millions of Americans, both children and adults, are still exposed to secondhand smoke in their homes and workplaces despite substantial progress in tobacco control. Secondhand smoke exposure in the workplace has been linked to an increased risk for heart disease and lung cancer among adult nonsmokers. The Surgeon General has concluded that smoke-free workplace policies are the only effective way to eliminate secondhand smoke exposure in the workplace. In the United States, 35 percent of children, or 21 million, live in homes where residents or visitors smoke in the home on a regular basis. Approximately 50 percent to 75 percent of children in the United States have detectable levels of cotinine, the breakdown product of nicotine, in their blood.
Flight Attendant Medical Research Institute (FAMRI)
FAMRI's mission is to sponsor scientific and medical research for the early detection, prevention, treatment and cure of diseases and medical conditions caused from exposure to tobacco smoke. Further, they seek to ensure that health-care providers ask the right questions of their patients about secondhand tobacco smoke exposure. According to an Association of Flight Attendants survey of their members, their most commonly identified on-the-job safety and health hazard is air quality and smoking. Overall, flight attendants have higher rates of a variety of diseases including higher rates of all cancers.
International Early Lung Cancer Action Program (I-ELCAP)
In 2000, the International Early Lung Cancer Action Program (I-ELCAP) was formed as a result of the recognized need for collaboration in order to achieve rapid advances in knowledge about CT screening and to translate these scientific findings into state-of-the-art guidelines for clinical practice in a timely manner. Led by Mount Sinai School of Medicine's Dr. Claudia Henschke, it is now the largest collaborative CT screening effort in the world consisting of a Coordinating Center and 56 participating institutions. Within this collaboration more than 50,000 individuals have undergone a baseline CT screening for lung cancer as of 2009. Study results include landmark findings showing that CT screening detects early lung cancer in a high proportion of people and that, in these cases, early intervention saves lives; that women are at twice the risk of lung cancer as equally-aged and equally-smoking men; and CT screening is highly cost-effective.